Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hitoshi Kiyoi

Showing results (21-30 of 270) with videos related to

Pageof 27
Sort By:
Cancer Science|July 30, 2021
Current progress and future perspectives of research on intravascular large B-cell lymphomaKazuyuki Shimada, Hitoshi Kiyoi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 25, 2017
[I.Genetic Abnormalities Associated with Acute Leukemia and a Development of Molecular Therapies]Yoshiya Adachi, Hitoshi Kiyoi
Leukemia Research|January 25, 2011
Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemiaYuichi Ishikawa, Hitoshi Kiyoi, Tomoki Naoe
International Journal of Hematology|September 9, 2005
Clinical significance of FLT3 in leukemiaHitoshi Kiyoi, Masamitsu Yanada, Kazutaka Ozekia
International Journal of Hematology|May 15, 2013
Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemiaAkihiro Tomita, Hitoshi Kiyoi, Tomoki Naoe
Oncotarget|November 8, 2017
Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemiaYoshiya Adachi, Yuichi Ishikawa, Hitoshi Kiyoi
International Journal of Hematology|August 22, 2024
Recent advances in AML with mutated NPM1Yuichi Ishikawa, Yoko Ushijima, Hitoshi Kiyoi
Blood|August 30, 2018
Biology and management of primary effusion lymphomaKazuyuki Shimada, Fumihiko Hayakawa, Hitoshi Kiyoi
Cancer Science|December 11, 2019
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor developmentHitoshi Kiyoi, Naomi Kawashima, Yuichi Ishikawa
Cancer Science|September 21, 2006
Nucleophosmin: a versatile molecule associated with hematological malignanciesTomoki Naoe, Tatsuya Suzuki, Hitoshi Kiyoi, et al.
Pageof 27

Showing results (21-30 of 270) with videos related to

Sort By:
Pageof 27
Cancer Science|July 30, 2021
Current progress and future perspectives of research on intravascular large B-cell lymphomaKazuyuki Shimada, Hitoshi Kiyoi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 25, 2017
[I.Genetic Abnormalities Associated with Acute Leukemia and a Development of Molecular Therapies]Yoshiya Adachi, Hitoshi Kiyoi
Leukemia Research|January 25, 2011
Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemiaYuichi Ishikawa, Hitoshi Kiyoi, Tomoki Naoe
International Journal of Hematology|September 9, 2005
Clinical significance of FLT3 in leukemiaHitoshi Kiyoi, Masamitsu Yanada, Kazutaka Ozekia
International Journal of Hematology|May 15, 2013
Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemiaAkihiro Tomita, Hitoshi Kiyoi, Tomoki Naoe
Oncotarget|November 8, 2017
Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemiaYoshiya Adachi, Yuichi Ishikawa, Hitoshi Kiyoi
International Journal of Hematology|August 22, 2024
Recent advances in AML with mutated NPM1Yuichi Ishikawa, Yoko Ushijima, Hitoshi Kiyoi
Blood|August 30, 2018
Biology and management of primary effusion lymphomaKazuyuki Shimada, Fumihiko Hayakawa, Hitoshi Kiyoi
Cancer Science|December 11, 2019
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor developmentHitoshi Kiyoi, Naomi Kawashima, Yuichi Ishikawa
Cancer Science|September 21, 2006
Nucleophosmin: a versatile molecule associated with hematological malignanciesTomoki Naoe, Tatsuya Suzuki, Hitoshi Kiyoi, et al.
Pageof 27